Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Open-label, Single-sequence, Cross-over, Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of IVIG-PEG Compared to Gamunex-C in Subjects With Primary Humoral Immunodeficiency
Conditions
Interventions
Gamunex-C
IVIG-PEG
Locations
10
United States
Alabama Allergy & Asthma Center
Birmingham, Alabama, United States
Allergy Associates of the Palm Beaches PA
North Palm Beach, Florida, United States
The South Bend Clinic Center for Research
South Bend, Indiana, United States
Institute for Asthma and Allergy
Chevy Chase, Maryland, United States
Washington University
St Louis, Missouri, United States
Optimed Research, LLC
Columbus, Ohio, United States
Start Date
September 2, 2020
Primary Completion Date
March 28, 2022
Completion Date
March 28, 2022
Last Updated
June 5, 2023
NCT03610802
NCT03394053
NCT07346859
NCT04902807
NCT07076446
NCT04944979
Lead Sponsor
Grifols Therapeutics LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions